Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct;62(4):550-554.
doi: 10.1002/mus.27034. Epub 2020 Aug 10.

Combination molecular therapies for type 1 spinal muscular atrophy

Yohei Harada  1 , Vamshi K Rao #  2 , Kapil Arya #  3 , Nancy L Kuntz  2 , Christine J DiDonato  2 , Galia Napchan-Pomerantz  4 , Amit Agarwal  5 , Vikki Stefans  6 , Masahisa Katsuno  7 , Aravindhan Veerapandiyan  3
Affiliations

Combination molecular therapies for type 1 spinal muscular atrophy

Yohei Harada et al. Muscle Nerve. 2020 Oct.

Abstract

Background: Data on combining molecular therapies that increase survival motor neuron protein for spinal muscular atrophy type 1 (SMA1) is lacking.

Methods: This was a retrospective study describing our centers' experiences in treating SMA1 patients with combination therapy.

Results: Five children received nusinersen and onasemnogene abeparvovec-xioi (onasemnogene). Four were receiving nusinersen prior to onasemnogene. Nusinersen was continued in three. Marked liver enzyme elevations resulted in prolonged corticosteroid treatment in two patients with hospitalization and liver biopsy in one; milder liver enzyme elevations were noted in the other two. One patient received onasemnogene first, and then nusinersen. No adverse effects were noted. All patients improved.

Conclusions: Combination molecular therapy is tolerated in SMA1 patients. Further studies are needed to determine whether there are circumstances in which combination therapy would be more efficacious than either monotherapy. Prolonged corticosteroid use and liver toxicity monitoring may be necessary with onasemnogene therapy.

Keywords: SMA; combine; gene therapy; nusinersen; onasemnogene.

PubMed Disclaimer

Comment in

References

REFERENCES

    1. U.S. Food and Drug Administration. AveXis, Inc Zolgensma (onasemnogene abeparvovec-xioi). [online]. https://www.fda.gov/vaccines-blood-biologics/zolgensma. Accessed July 19, 2020.
    1. U.S. Food and Drug Administration USFaD. SPINRAZA (nusinersen) injection, for intrathecal use. [online]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209531lbl.pdf. Accessed July 19, 2020.
    1. Ramdas S, Servais L. New treatments in spinal muscular atrophy: an overview of currently available data. Expert Opin Pharmacother. 2020;21:307-315.
    1. Veerapandiyan A. Spinal muscular atrophy. MedLink Neurology. July 5, 2019. MedLink Corporation. 2019.
    1. Darras BT, Farrar MA, Mercuri E, et al. An integrated safety analysis of infants and children with symptomatic spinal muscular atrophy (SMA) treated with Nusinersen in seven clinical trials. CNS Drugs. 2019;33:919-932.

Publication types

LinkOut - more resources